Partial and full agonists of A1 adenosine receptors

Details Partial and full agonists of A1 adenosine receptors Partial and full agonists of A1 adenosine receptors

2006-04-04

2006-04-04

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027210

Reexamination Certificate

active

07022681

ABSTRACT:
Disclosed are A1adenosine receptor agonists of the formula:wherein:R1is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;R2is hydrogen, halo, trifluoromethyl, or cyano;R3is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl,R4and R5are independently hydrogen or optionally substituted acyl;X is a covalent bond or lower alkylene optionally substituted by cycloalkyl;X1is a covalent bond or alkylene;Y is a covalent bond or lower alkylene optionally substituted by hedroxy or cycloalkyl; andZ is —C≡C—, —R6C═CR7—, or —CHR6CHR7—, in which R6and R7at each occurrence are hydrogen or lower alkyl.

REFERENCES:
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5589467 (1996-12-01), Lau et al.
patent: RE36494 (2000-01-01), Olsson et al.
patent: 6492348 (2002-12-01), Bays et al.
patent: 6677316 (2004-01-01), Bays et al.
patent: 2004/0162422 (2004-08-01), Hall et al.
patent: 0181128 (1989-10-01), None
patent: (L) 0181128 (1989-10-01), None
patent: WO 9733591 (1997-09-01), None
patent: (M) WO98/16539 (1998-04-01), None
patent: WO98/16539 (1998-04-01), None
patent: WO 9967262 (1999-12-01), None
patent: WO 02074780 (2002-09-01), None
Clark et al., “Partial Agonists and G Protein-Coupled Receptor Desensitization,”Trends in Pharmaceutical Science, 20, 279-286 (Jul., 1999).
Feoktistov et al. (I), “Adenosine A2BReceptors: A Novel Therapeutic Target in Asthma?”Trends in Pharmaceutical Science, 19, 148-153 (Apr., 1998).
Feoktistov et al. (II), “Adenosine A2BReceptors as Therapeutic Targets,”Drug Development Research, 45(3-4), 198-206 (1998).
Wu et al., “A Partial Agonist of the A1-Adenosine Receptor Selectively Slows AV Conduction in Guinea Pig Hearts,”Am. J. Physiology(Heart Circulation Physiology), 280(1, Pt. 2), pp. H334-H343, (Jan., 2001).
[R] Dhalla et al., “Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands,” □□Current Topics in Medicinal Chemistry, 3(4), 369-385 (2003).
Dhalla et al., “Pharmacology and Therapeutic Applications of A1Adenosine Receptor Ligands,”Current Topics in Medicinal Chemistry, 3(4), 369-385 (2003).††.
(S) Shah et al., “Pharmacokinitics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1 Agonist, RPR749, in Healthy Subjects,” American Journal of Therapeutics, 11(3), 175-189 (2004).
(T) van Schaick et al., “Pharmacokinetic-pharmacodynamic Modelling of the Antilipolytic and Anti-Ketotic Effects of Adenosine A1-Receptor Agonist N6-(p-sulfophenyl)adenosine in Rats,” British Journal of Pharmacology, 122, 525-533 (1997).
(U) van Schaick e tal. (II), “Selectivity of Action of 8-Alkylthio Analogfues of N6-Cyclopentyladenosine in vivo: Haemodynamic versus Anti-Lipolytic Responses in Rats,” British Journal of Pharmacology, 124, 607-618 (1998).
Shah et al., “Pharmacokinitics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1Agonists, RPR749, in Healthy Subjects,”American Journal of Therapeutics, 11(3), 175-189 (2004)††.
van Schaick et al., “Pharmacokinetic-pharmacodynamic Modelling of the Antilipolytic and Anti-Ketotic Effects of Adenosine A1-Receptor Agonist N6-(p-sulfophenyl)adenosine in Rats,”British Journal of Pharmacology, 122, 525-533 (1997).††.
van Schaick et al. (II), “Selectivity of Action of 8-Alkylthio Analogfues of N6-Cyclopentyladenosine in vivo: HaemodynamicversusAnti-Lipolytic Responses in Rats,”British Journal of Pharmacology, 124, 607-618 (1998).††.

Affiliated with

Also associated with

Rating

Partial and full agonists of A1 adenosine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Partial and full agonists of A1 adenosine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partial and full agonists of A1 adenosine receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3588294